Norbert Bischofberger (Kronos)
March 4, 2021 11:09 AM EST
R&D

Kro­nos seals pact with reg­u­la­tors to hunt AML with pre­vi­ous­ly off-lim­its bio­mark­er end­point

Max Gelman

Senior Editor

As head of R&D at Gilead, Nor­bert Bischof­berg­er shelved the SYK in­hibitor en­tosple­tinib af­ter it proved to need too lengthy a de­vel­op­ment cy­cle to win …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

J&J takes 340B fight with fed­er­al gov­ern­ment to court

Dan­ish biotech Gubra touts ear­ly weight loss da­ta in hot amylin field

Af­ter stock slides, Am­gen ad­dress­es bone den­si­ty talk on obe­si­ty drug

New can­cer class heats up as BioN­Tech buys out Chi­na part­ner and its PD-L1/VEGF drug

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times